Rapidly acting antitumoral antiangiogenic therapies.
We deal with a biophysical description of antitumor antiangiogenic therapies. In particular, by means of some simple models, we study the possible effects of the delay between the drug consumption by endothelial cells and their death on the outcome of the therapy. We have found that this time lag implies an increase in the minimal dose guaranteeing tumor eradication and, if the delay is greater than a meaningful threshold, it may preclude the total regression. These results might be of interest in better understanding the causes underlying the contradictory literature on the clinical trials of antiangiogenic therapies.
d'Onofrio
Alberto
A
European Institute of Oncology, Division of Epidemiology and Biostatistics, Via Ripamonti 435, I20141 Milano, Italy. alberto.donofrio@ieo.it
D043168:Angiostatins / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D016923:Cell Death / Q000187:drug effects; D003198:Computer Simulation; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D042783:Endothelial Cells / Q000187:drug effects; D006801:Humans; D008962:Models, Theoretical; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
D000970:Antineoplastic Agents; D043168:Angiostatins